TAK-438(also known as Vonoprazan Fumarate) is a first-in-class potassium-competitive acid blocker (P-CAB) which competitively blocks the potassium-binding site of H+, K+-adenosine triphosphate (ATP)ase. It is used for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Vonoprazan fumarate for the management of acid-related diseases.
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
 Y.Hori, et al, J. Pharmacol. Exp. Ther., 2010, 335(1), pp 231-238.
 J.M.Shin, et al, J. pharmacol. Exp. Ther., 2011, 339(2), pp 412-420.
 Y.Hori, et al, J. Pharmacol. Exp. Ther., 2011, 337(3), pp 797-804.
 H.Echizen, et al, Clin. Pharmacokinet., 2016, 55(4), pp 409-418.